We have deep experience in successfully conducting clinical trials for oncology compounds in today's marketplace. We will maintain tight schedules while working closely with regulatory authorities, physicians and our leadership team to create a dynamic portfolio of compounds.

Product Development and Clinical Trials



Darinaparsin (ZIO-101) is the first of a new class of organic arsenicals that are potentially safer and more active for cancer treatment than approved inorganic arsenicals. It is in a late Phase II trial in patients with primary liver cancer, advanced myeloma and patients with diverse hematological malignancies. A Phase I trial has also begun involving oral administration.

Palifosfamide (ZIO-201) is a proprietary formulation of isophosphoramide mustard, the active metabolite of ifosfamide. Ifosfamide is an alkylating drug used to treat diverse cancers including testicular cancer, sarcoma, and lymphoma. A Phase II clinical trial in sarcoma is nearing completion, and a Phase I/II sarcoma combination trial is now underway.

Indibulin (ZIO-301) is a novel anti-cancer agent that binds to tubulin, one of the essential proteins for chromosomal segregation, and targets mitosis like the taxanes and Vinca alkaloids. It is available as both an oral and an intravenous form. Indibulin has a pharmacologic profile that is different from other tubulin inhibitors currently on the market. Indibulin binds to a site on tubulin that is different from the taxanes or Vinca alkaloid binding sites. In contrast to taxanes, which stabilize tubulin polymers, indibulin destabilizes tubulin polymerization. It is currently in a late Phase I trial in Europe and the United States, and a Phase I/II combination trial has been initiated.